[Physiological trials with MIF-I in Parkinson's disease (author's transl)].


The writers present some physiological (and not therapeutic) acute and sub-acute trials with tripeptide: L-propyl-L-leucyl-glycine amide (M.I.F.-I) in Parkinson's Disease. This work confirms the earlier observation that M.I.F.-I employed alone or in combination with Levodopa is active against Parkinson's disease. The writers evoke the hypothesis that this… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.